Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BeBetter MedSHSE:688759 -17.26%4 EV-to-FCF is -72.02 as of Jul. 28, 2026. GuruFocus rates SHSE:688759 with a GF Score™ of 4/100. Among 341 Biotechnology companies, BeBetter Med ranks worse than 293254.84% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, BeBetter Med's Enterprise Value is ¥11,101.57 Mil.
BeBetter Med's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ¥-154.15 Mil. Therefore, BeBetter Med's EV-to-FCF for today is -72.02.
The historical rank and industry rank for BeBetter Med's EV-to-FCF or its related term are showing as below:
SHSE:688759'
s EV-to-FCF Range Over the Past 10 Years
Min: -80.69 Med: 0 Max: 0
Current: -66.56
SHSE:688759's EV-to-FCF is ranked worse than 100% of 341
companies
in the Biotechnology industry
Industry Median: 14.64
vs SHSE:688759: -66.56
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BeBetter Med's PE Ratio (TTM) for today is calculated as:
BeBetter Med's share price for today is ¥23.20.
BeBetter Med's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-0.426.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
BeBetter Med EV-to-FCF Related Terms
BeBetter Med EV-to-FCF Historical Data
* Premium members only.
The historical data trend for BeBetter Med's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688759 vs VRTX, REGN, RVMD: EV-to-FCF Comparison
For the Biotechnology subindustry, BeBetter Med's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeBetter Med EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeBetter Med's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where BeBetter Med's EV-to-FCF falls into.
BeBetter Med's current Enterprise Value is ¥11,101.57 Mil.
BeBetter Med's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-154.15 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BeBetter Med (SHSE:688759) has a EV-to-FCF of -72.02 as of Jul. 28, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on BeBetter Med and its competitors. According to the industry distribution chart, BeBetter Med ranks #999999 out of 341 companies in the Biotechnology industry.
Is BeBetter Med's EV-to-FCF too high?
BeBetter Med's current EV-to-FCF is -72.02. Based on the distribution chart, BeBetter Med ranks #999999 out of 341 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BeBetter Med has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does BeBetter Med's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BeBetter Med ranks #999999 out of 341 companies for EV-to-FCF. This places BeBetter Med in the lower half of its industry. The industry median EV-to-FCF is 14.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.64, based on 341 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on BeBetter Med and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BeBetter Med's current EV-to-FCF is -72.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeBetter Med stock overvalued right now?
BeBetter Med (SHSE:688759) has a current EV-to-FCF of -72.02. The current EV-to-FCF is -72.02. BeBetter Med's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For BeBetter Med (SHSE:688759), the current EV-to-FCF is -72.02 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BeBetter Med Inc is a biopharmaceutical company based in China, focusing on independent research and development of drugs. The company focuses on developing novel medicines for treating cancers, autoimmune diseases, and other severe conditions. Key products include the PI3K/HDAC dual inhibitor BEBT-908 and multiple drugs in clinical trial phases targeting cancers. It's a United States subsidiary BeBetter Pharma specializes in next-generation siRNA therapeutics using proprietary delivery platforms aimed at complex diseases like kidney disorders, metabolic and liver diseases, and neurodegenerative conditions. Its pipeline includes oral and injectable drug candidates, some in late-stage trials, and aims to address unmet medical needs through novel mechanisms.
4GF Score
Get the complete analysis for SHSE:688759
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688759 has been successfully added to your 
